title: Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression.
abstract: BACKGROUND
  Despite the fact that carbamazepine (CBZ) is frequently added to the existing tricyclic antidepressant (TCA) therapy, to date little is known about serum levels of pharmacologically active hydroxy metabolites of TCAs, as well as about possible changes in free (non-protein-bound) concentrations of these drugs and their metabolites during such combination treatment of depression.
  
  
  OBJECTIVE
  The aim of this study was to evaluate the effect of CBZ on steady-state total and free serum concentrations of imipramine (IMI) and its metabolites, desipramine (DMI), 2-hydroxyimipramine and 2-hydroxydesipramnine, in depressed patients. In addition, the free and total serum concentrations of CBZ and 10,11-epoxycarbamazepine were measured.
  
  
  METHODS
  Thirteen patients with DSM-III-R diagnosis of major depression were enrolled in the study. All patients hospitalised at the Department of Psychiatry, Collegium Medicum, Jagiellonian University were treated with IMI at a dose of 2 mg/kg per day for 3 weeks, after which CBZ at a dose of 400 mg/day was added. Steady-state serum concentrations of IMI, CBZ and their metabolites were assayed by HPLC. Free drug concentrations were measured by ultrafiltration.
  
  
  RESULTS
  After 2 weeks of combination therapy a significant decrease in mean steady-state total serum concentrations of IMI (from 168.84 +/- 102.18 to 98.12 +/- 43.79 ng/ml) and DMI (from 293.89 +/- 171.93 to 221.85 +/- 153.21 ng/ml) was observed. Simultaneously, steady-state serum concentrations of total hydroxy metabolites and free IMI and its metabolites, measured just before and 2 weeks after CBZ were started, did not differ significantly. In consequence, a significant increase in free fraction of the parent drug was observed (3.36 +/- 3.24% vs 5.75 +/- 3.60%). Also free fraction of DMI tended to be higher after CBZ addition.
  
  
  CONCLUSIONS
  CBZ affects not only the metabolism of IMI and its metabolites, but also their protein binding. Therefore, despite considerable reductions in total serum levels of IMI and DMI, but when the unchanged free fraction concentration of these compounds is maintained, a dosage elevation of IMI does not seem to be necessary after CBZ addition to TCA therapy.
authors: Department of Pharmacokinetics and Physical Pharmacy, Jagiellonian University, Kraków, Poland. mfszymur@cyf-kr.edu.pl
authors: J
authors: J
authors: Szymura-Oleksiak
authors: E
authors: E
authors: Wyska
authors: A
authors: A
authors: Wasieczko
mesh_terms: D000929:Antidepressive Agents, Tricyclic / Q000493:pharmacokinetics*; D018692:Antimanic Agents / Q000493:pharmacokinetics*; D001711:Biotransformation; D002220:Carbamazepine / Q000493:pharmacokinetics*; D003866:Depressive Disorder / Q000378:metabolism*; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007099:Imipramine / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged; D011485:Protein Binding; D014462:Ultrafiltration
chemical_list: D000929:Antidepressive Agents, Tricyclic; D018692:Antimanic Agents; D002220:Carbamazepine; D007099:Imipramine